

57

the restriction, R⁶ was defined as -H only. Also, as described below, Applicants have selected a single compound and treatment of osteoporosis for examination.

As suggested by the Office at paragraph 5 of the restriction requirement, Applicants have reduced the scope of the compounds that new independent claim 29 recites and they propose setting forth the scope of compounds that original claims 1-10 and new claims 23-31 now recite. Variable groups R⁵, R⁷ and R⁸ are absent from the scope of the new claim set. The clinical conditions that are listed in claim 29 are also reduced to treating innate immune suppression conditions. The new claims are more easily searched and Applicants request the Office to consider treating the subject matter that claim 29 recites as a single invention for purposes of examination and to consider the sufficiency of the written description in the disclosure for the new claims.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 501536.

Respectfully submitted,

Hollis-Eden Pharmaceuticals, Inc.

Date: 6-10-05 By: Daryl D. Muenchau
Daryl D. Muenchau, Reg. No. 36,616
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, CA 92121
P: 858-320-2569
F: 858-558-6470